Epidermodysplasia Verruciformis (EV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Epidermodysplasia Verruciformis (EV) Market Outlook
Thelansis’s “Epidermodysplasia
Verruciformis (EV) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Epidermodysplasia
Verruciformis (EV) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
Epidermodysplasia
Verruciformis (EV) Overview
Epidermodysplasia
verruciformis (EV) is a rare, lifelong, cutaneous, autosomal recessive immune
system disorder characterized by increased susceptibility to cutaneous human
papillomavirus (HPV) infection beginning in childhood. The disease usually
manifests during infancy (7.5% of cases), youth (61.5% of cases), or puberty
(22% of cases) with the progressive development of hyperpigmented or
hypopigmented flat wart-like papules, irregular reddish-brown plaques,
seborrheic keratosis-like lesions and pityriasis Versicolor-like macules on the
trunk, neck, face, dorsal hands, and feet. Loss-of-function mutations can cause
EV in either of two adjacent genes, EVER1/TMC6 or EVER2/TMC8 (17q25.3), which
code for membrane proteins that form a complex with the zinc transporter
protein ZnT-1 in the ER membrane of keratinocytes. In epidermodysplasia
verruciformis, two clinical presentations have been described. Flat-topped
papules and plaques with a scaly surface and irregular borders that are white,
pink, reddish-brown, dark brown, or violet. Verrucous or seborrhoeic
keratoses-like lesions. These are raised brown warty lesions.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment